Supplementary Materials for

Interchangeability of light and virtual microscopy for histopathological evaluation of prostate cancer

Renata Zelic, Francesca Giunchi, Luca Lianas, Cecilia Mascia, Gianluigi Zanetti, Ove Andrén, Jonna Fridfeldt, Jessica Carlsson, Sabina Davidsson, Luca Molinaro, Per Henrik Vincent, Lorenzo Richiardi, Olof Akre, Michelangelo Fiorentino, Andreas Pettersson

Correspondence to: renata.zelic@ki.se

Conflict of Interest: None to declare.

Table of Contents:

Supplementary methods
Supplementary Table S1. Histopathological characteristics evaluated on the slide level for 352
slides which were evaluated by both reviewers using both the light and virtual microscopy 6
Supplementary Table S2. Case-level summary of histopathological characteristics for 60 cases
Supplementary Table S3. Reasons for exclusion of diagnostic slides
Supplementary Figure S1. Bland and Altman plot of the intra-method intra-observer
agreement for biopsy core length measured in millimeters, evaluated on the core level9
Supplementary Figure S2. Bland and Altman plot of the intra-method intra-observer
agreement for length of tumor in the biopsy core measured in millimeters, evaluated on the
core level
Supplementary Figure S3. Intra-method intra-observer agreement for characteristics evaluated
on the core level
Supplementary Figure S4. Intra-method intra-observer agreement for characteristics evaluated
on the slide level
Supplementary Figure S5. Bland and Altman plot of the intra-method intra-observer
agreement for the percentage of Gleason pattern 4, evaluated on the core level
Supplementary Figure S6. Bland and Altman plot of the intra-method inter-observer
agreement for biopsy core length measured in millimeters, evaluated on the core level 14
Supplementary Figure S7. Bland and Altman plot of the intra-method inter-observer
agreement for the length of tumor in the biopsy core measured in millimeters, evaluated on
the core level
Supplementary Figure S8. Intra-method inter-observer agreement for characteristics evaluated
on the core level
Supplementary Figure S9. Intra-method inter-observer agreement for characteristics evaluated
on the slide level
Supplementary Figure S10. Bland and Altman plot of the intra-method inter-observer
agreement for the percentage of Gleason pattern 4, evaluated on the core level

Supplementary Figure S11. Bland and Altman plot of the inter-method intra-observer
agreement for the biopsy core length measured in millimeters, evaluated on the core level19
Supplementary Figure S12. Bland and Altman plot of the inter-method intra-observer
agreement for the length of tumor in the biopsy core measured in millimeters, evaluated on
the core level
Supplementary Figure S13. Inter-method intra-observer agreement for characteristics
evaluated on the core level
Supplementary Figure S14. Inter-method intra-observer agreement for characteristics
evaluated on the slide level
Supplementary Figure S15. Bland and Altman plot of the inter-method intra-observer
agreement for the percentage of Gleason pattern 4, evaluated on the core level
Supplementary Figure S16. Bland and Altman plot of the inter-method inter-observer
agreement for the biopsy core length measured in millimeters, evaluated on the core level24
Supplementary Figure S17. Bland and Altman plot of the inter-method inter-observer
agreement for the length of tumor in the biopsy core measured in millimeters, evaluated on
the core level
Supplementary Figure S18. Inter-method inter-observer agreement for characteristics
evaluated on the core level
Supplementary Figure S19. Inter-method inter-observer agreement for characteristics
evaluated on the slide level
Supplementary Figure S20. Bland and Altman plot of the inter-method inter-observer
agreement for the percentage of Gleason pattern 4, evaluated on the core level
Supplementary Figure S21. Bland and Altman plot of the intra-method intra-observer
agreement for the total biopsy length measured in millimeters, evaluated on the case level 29
Supplementary Figure S22. Bland and Altman plot of the intra-method intra-observer
agreement for the total length of tumor in the biopsy measured in millimeters, evaluated on
the case level
Supplementary Figure S23. Intra-method intra-observer agreement evaluated on the case level
Supplementary Figure S24. Bland and Altman plot of the intra-method inter-observer

agreement for the total biopsy length measured in millimeters, evaluated on the case level .. 32

Supplementary Figure S25. Bland and Altman plot of the intra-method inter-observer
agreement for the total length of tumor in the biopsy measured in millimeters evaluated on the
case level
Supplementary Figure S26. Intra-method inter-observer agreement evaluated on the case level
Supplementary Figure S27. Bland and Altman plot of the inter-method intra-observer
agreement for the total biopsy length measured in millimeters, evaluated on the case level 35
Supplementary Figure S28. Bland and Altman plot of the inter-method intra-observer
agreement for the total length of tumor in the biopsy measured in millimeters, evaluated on
the case level
Supplementary Figure S29. Inter-method intra-observer agreement evaluated on the case level
Supplementary Figure S30. Bland and Altman plot of the inter-method inter-observer
agreement for the total biopsy length measured in millimeters, evaluated on the case level 38
Supplementary Figure S31. Bland and Altman plot of the inter-method inter-observer
agreement for the total length of tumor in the biopsy measured in millimeters, evaluated on
the case level
Supplementary Figure S32. Inter-method inter-observer agreement evaluated on the case level

Supplementary methods

The virtual microscopy system

The virtual microscopy system was developed by Centre for Advanced Studies, Research and Development in Sardinia (CRS4, <u>www.crs4.it</u>) and it comprises two integrated components (Figure 1):

- ome_seadragon (https://github.com/crs4/ome_seadragon), a plugin for the Open Microscopy Environment Remote Objects (OMERO) platform,¹ which enables viewing, handling and annotation of the 3DHistech images. The image management is based on the OMERO.server which supports over 140 different image formats and allows for storing of meta-information (e.g., classification TAGs or Regions of Interests (ROIs)). The ome_seadragon simplifies the integration of the images stored within OMERO into external web systems,² adds Deep Zoom Image format (DZI) support to OMERO and, through OpenSlide libraries (https://openslide.org),³ increases the number of supported image formats. The user side of ome_seadragon is a specialized viewer based on the open source viewer OpenSeadragon (https://openseadragon.github.io). This viewer acts as a Virtual Microscope and can be easily embedded into external web services. Real time annotation tools which are based on Paper.js libraries (http://paperjs.org) enable navigation on a digital slide and annotation by drawing different 2D shapes, as well as taking precise measures (e.g., ROI length or area).
- 2. The ProMort Image Management System (<u>https://github.com/crs4/ProMort</u>), a web application developed by the CRS4 to manage the review worklist and clinical annotation process related to the ProMort study. The clinical annotation comprises two main steps: the definition of the ROIs and the clinical annotation of the ROIs. By embedding the ome_seadragon viewer (i.e., the Virtual Microscope), the ProMort Image Management System allows users to navigate and annotate digital slides while creating new ROIs. Clinical annotations are performed via a dedicated user interface which has been designed specifically for ProMort.

4



Figure 1. A simplified schematic representation of the virtual microscopy system

Abbreviations: OMERO, The Open Microscopy Environment Remote Objects; ROIs, Regions of interest

Notes: Histology slide image is a cropped version of the Cancer Genome Atlas (TCGA-PRAD) image which is freely available at the Genomic Data Commons (GDC) portal and is a part of the Open Access data tier (the dbGaP accession phs000178.v11.p8); Server icon – "Gorilla-server.svg", a server icon in the Gorilla icon theme style by George Boukeas licensed under CC-BY-SA 3.0. Taken from Wikimedia commons; Django logo – "Django logo" is a trademark of Django Software Foundation, licensed under CC-BY-SA 3.0. Taken from Django community; Angular logo – "Angular logo" by the Angular team, licensed under CC BY 4.0. Taken from Angular presskit; OMERO mark – "OME mark", by the Open Microscopy Environment, licensed under CC BY 4.0. Taken from OME artwork; Redis logo – "Redis logo"- is a trademark of Redis Labs Ltd, licensed under the 3-Clause BSD license. Any rights therein are reserved to Redis Labs Ltd. Any use by CRS4 is for referential purposes only and does not indicate any sponsorship, endorsement or affiliation between Redis and CRS4

References:

- 1 Allan, C. *et al.* OMERO: flexible, model-driven data management for experimental biology. *Nat Methods* **9**, 245-253, doi:10.1038/nmeth.1896 (2012).
- Lianas, L. *et al.* CyTest An Innovative Open-source Platform for Training and Testing in Cythopathology. *Procd Soc Behv* 228, 674-681, doi:10.1016/j.sbspro.2016.07.103 (2016).
- 3 Goode, A., Gilbert, B., Harkes, J., Jukic, D. & Satyanarayanan, M. OpenSlide: A vendorneutral software foundation for digital pathology. *J Pathol Inform* 4, 27, doi:10.4103/2153-3539.119005 (2013).

	Light microscopy			Virtual microscopy		
	Reviewer 1.1	Reviewer 1.2	Reviewer 2	Reviewer 1.1	Reviewer 1.2	Reviewer 2
	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
Acute inflamm	ation					
No	325 (92.33)	325 (92.33)	335 (95.17)	324 (92.05)	322 (92.00)	335 (95.99)
Yes	27 (7.67)	27 (7.67)	17 (4.83)	28 (7.95)	28 (8.00)	14 (4.01)
Missing	-	-	-	-	2	3
Chronic inflam	mation					
No	215 (61.08)	218 (61.93)	247 (70.17)	122 (34.66)	132 (37.71)	224 (64.18)
Yes	137 (38.92)	134 (38.07)	105 (29.83)	230 (65.34)	218 (62.29)	125 (35.82)
Missing	-	-	-	-	2	3
High-grade pro	static intraepith	nelial neoplasia				
No	329 (93.47)	336 (95.45)	335 (95.17)	317 (90.06)	325 (92.86)	333 (95.42)
Yes	23 (6.53)	16 (4.55)	17 (4.83)	35 (9.94)	25 (7.14)	16 (4.58)
Missing	-	-	-	-	2	3
Postatrophic hy	perplasia					
No	339 (96.31)	343 (97.44)	336 (95.45)	337 (95.74)	339 (96.86)	339 (97.13)
Yes	13 (3.69)	9 (2.56)	16 (4.55)	15 (4.26)	11 (3.14)	10 (2.87)
Missing	-	-	-	-	2	3
Periglandular in	nflammation					
No	259 (73.58)	269 (76.42)	307 (87.22)	199 (56.53)	211 (60.29)	273 (78.22)
Yes	93 (26.42)	83 (23.58)	45 (12.78)	153 (43.47)	139 (39.71)	76 (21.78)
Missing	-	-	-	-	2	3
Intraglandular i	inflammation					
No	322 (91.48)	321 (91.19)	335 (95.17)	305 (86.65)	314 (89.71)	333 (95.42)
Yes	30 (8.52)	31 (8.81)	17 (4.83)	47 (13.35)	36 (10.29)	16 (4.58)
Missing	-	-	-	-	2	3
Stromal inflam	mation					
No	279 (79.26)	258 (73.30)	257 (73.01)	187 (53.13)	207 (59.14)	258 (73.93)
Yes	73 (20.74)	94 (26.70)	95 (26.99)	165 (46.88)	143 (40.86)	91 (26.07)

Supplementary Table S1. Histopathological characteristics evaluated on the slide level for 352 slides which were evaluated by both reviewers using both the light and virtual microscopy

Abbreviations: N, Sample size; Reviewer 1.1, First review by Reviewer 1; Reviewer 1.2, Second review by Reviewer 1

	Light microscopy			Virtual microscopy		
	Reviewer 1.1	Reviewer 1.2	Reviewer 2	Reviewer 1.1	Reviewer 1.2	Reviewer 2
	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
Biopsy core le	ngth (mm) ¹					
Mean (SD)	73.53 (26.10)	72.33 (25.04)	72.45 (26.36)	77.55 (25.47)	78.09 (26.33)	75.11 (25.30)
Positive core						
No	3 (5.00)	2 (3.33)	3 (5.00)	2 (3.33)	2 (3.33)	2 (3.33)
Yes	57 (95.00)	58 (96.67)	57 (95.00)	58 (96.67)	58 (96.67)	58 (96.67)
Tumor length	$(mm)^1$					
Mean (SD)	34.49 (26.70)	32.38 (26.32)	34.60 (27.10)	30.35 (26.17)	30.95 (25.97)	29.20 (26.85)
Primary Gleas	on Grade					
3	16 (28.07)	17 (29.31)	15 (26.32)	16 (27.59)	16 (27.59)	18 (31.03)
4	34 (59.65)	40 (68.97)	32 (56.14)	37 (63.79)	36 (62.07)	37 (63.79)
5	7 (12.28)	1 (1.72)	10 (17.54)	5 (8.62)	6 (10.34)	3 (5.17)
Secondary Gle	eason grade					
3	12 (24.14)	14 (24.14)	12 (21.05)	15 (25.86)	12 (20.69)	15 (25.86)
4	28 (41.38)	24 (41.38)	29 (50.88)	28 (48.28)	28 (48.28)	25 (43.10)
5	17 (34.48)	20 (34.48)	16 (28.07)	15 (25.86)	18 (31.03)	18 (31.03)
Gleason score	2					
6	7 (12.28)	9 (15.52)	7 (12.28)	8 (13.79)	8 (13.79)	10 (17.24)
7	14 (24.56)	13 (22.41)	13 (22.81)	15 (25.86)	12 (20.69)	13 (22.41)
8	14 (24.56)	15 (25.86)	14 (24.56)	15 (25.86)	15 (20.69)	14 (24.14)
9	20 (35.09)	21 (36.21)	20 (35.09)	20 (34.48)	22 (37.93)	21 (36.21)
10	2 (3.51)		3 (5.26)		1 (1.72)	
Gleason Grade	e Groups ³					
1	7 (12.28)	9 (15.52)	7 (12.28)	8 (13.79)	8 (13.79)	10 (17.24)
2	9 (15.79)	8 (13.79)	8 (14.04)	8 (13.79)	8 (13.79)	18 (13.79)
3	5 (8.77)	5 (8.62)	5 (8.77)	7 (12.07)	4 (6.90)	5 (8.62)
4	14 (24.56)	15 (25.86)	14 (24.56)	15 (25.86)	15 (25.86)	14 (24.14)
5	22 (38.60)	21 (36.21)	23 (40.35)	20 (34.48)	23 (39.66)	21 (36.21)
Perineural inva	asion ⁴	. ,		. ,	. ,	. ,
No	35 (61.40)	40 (68.97)	36 (63.16)	40 (68.97)	39 (67.24)	39 (67.24)
Yes	22 (38.60)	18 (31.03)	21 (36.84)	18 (31.03)	19 (32.76)	19 (32.76)

Supplementary Table S2. Case-level summary of histopathological characteristics for 60 cases

Tes22 (38.60)18 (31.03)21 (30.84)18 (31.03)19 (32.76)Abbreviations: N, Sample size; SD, Standard deviation; Reviewer 1.1, First review by Reviewer 1; Reviewer1.2, Second review by Reviewer 1¹ Sum of all the core level measurements per case² The highest core-level Gleason score³ The highest Gleason core-level Grade Group⁴ Perineural invasion present on at least one core for one case

_	Light microscopy			Virtual microscopy		
	Reviewer 1.1	Reviewer 1.2	Reviewer 2	Reviewer 1.1	Reviewer 1.2	Reviewer 2
	N=362	N=362	N=362	N=417	N=417	N=417
	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
Rejection reason						
Technically inadequate	-	-	-	2 (0.48)	1 (0.24)	2 (0.24)
No prostate tissue	4 (1.10)	6 (1.66)	5 (1.38)	5 (1.20)	5 (1.20)	6 (1.20)
No tissue	3 (0.83)	-	2 (0.55)	1 (0.24)	1 (0.24)	1 (0.24)
Duplicate slide	-	-	-	54 (12.95)	55 (12.95)	54 (12.47)

Supplementary Table S3. Reasons for exclusion of diagnostic slides

Abbreviations: N, Sample size; Reviewer 1.1, First review by Reviewer 1; Reviewer 1.2, Second review by Reviewer 1

Supplementary Figure S1. Bland and Altman plot of the intra-method intra-observer agreement for biopsy core length measured in millimeters, evaluated on the core level



Supplementary Figure S2. Bland and Altman plot of the intra-method intra-observer agreement for length of tumor in the biopsy core measured in millimeters, evaluated on the core level



Supplementary Figure S3. Intra-method intra-observer agreement for characteristics evaluated on the core level

Primary Gleason pattern Light 1.1 vs. Light 1.2 256 0.79 (0.72, 0.86) Virtual 1.1 vs. Virtual 1.2 253 0.84 (0.78, 0.91) Secondary Gleason pattern 256 0.67 (0.60, 0.75) Virtual 1.1 vs. Light 1.2 256 0.67 (0.60, 0.75) Virtual 1.1 vs. Virtual 1.2 253 0.66 (0.58, 0.73)
Virtual 1.1 vs. Virtual 1.2 Image: Constraint of the second and t
Secondary Gleason pattern Light 1.1 vs. Light 1.2 Virtual 1 1 vs. Virtual 1 2 Light 1.1 vs. Light 1.2 Light 1.1 vs. L
Light 1.1 vs. Light 1.2 \rightarrow 256 0.67 (0.60, 0.75)
Virtual 1.1 vs. Virtual 1.2
Gleason score
Light 1.1 vs. Light 1.2 \mapsto 256 0.82 (0.78, 0.87)
Virtual 1.1 vs. Virtual 1.2 🛏 253 0.81 (0.77, 0.86)
Gleason Grade Groups
Light 1.1 vs. Light 1.2 \mapsto 256 0.85 (0.81, 0.88)
Virtual 1.1 vs. Virtual 1.2 → 253 0.84 (0.80, 0.88)
Cribriform pattern
Light 1.1 vs. Light 1.2 → 256 0.68 (0.59, 0.77)
Virtual 1.1 vs. Virtual 1.2 Image: Virtual 1.2 253 0.79 (0.72, 0.87)
Poorly formed glands
Light 1.1 vs. Light 1.2
Virtual 1.1 vs. Virtual 1.2 Example 253 0.67 (0.57, 0.77)
Comedonecrosis
Light 1.1 vs. Light 1.2
Virtual 1.1 vs. Virtual 1.2
Perineural invasion
Light 1.1 vs. Light 1.2
Virtual 1.1 vs. Virtual 1.2 — 253 0.60 (0.47, 0.73)
Intraductal carcinoma
Light 1.1 vs. Light 1.2
Virtual 1.1 vs. Virtual 1.2
Mucinous carcinoma
Light 1.1 vs. Light 1.2
Virtual 1.1 vs. Virtual 1.2
-0.2 0.0 0.2 0.4 0.6 0.8 1.0
Cohen's kanna

Supplementary Figure S4. Intra-method intra-observer agreement for characteristics evaluated on the slide level

Comparison	Sample size	Cohen's kappa (95% CI)
Acute inflammation		
Light 1.1 vs. Light 1.2	352	0.52 (0.35, 0.69)
Virtual 1.1 vs. Virtual 1.2	350	0.69 (0.55, 0.83)
Chronic inflammation		
Light 1.1 vs. Light 1.2	352	0.47 (0.37, 0.56)
Virtual 1.1 vs. Virtual 1.2	350	0.66 (0.58, 0.74)
High-grade prostatic intraepithelial neoplasia		
Light 1.1 vs. Light 1.2	352	0.43 (0.23, 0.63)
Virtual 1.1 vs. Virtual 1.2	350	0.53 (0.37, 0.69)
Intraglandular inflamation		
Light 1.1 vs. Light 1.2	352	0.52 (0.36, 0.68)
Virtual 1.1 vs. Virtual 1.2	350	0.69 (0.57, 0.81)
Postatrophic hyperplasia		
Light 1.1 vs. Light 1.2	352	0.53 (0.28, 0.79)
Virtual 1.1 vs. Virtual 1.2	350	0.60 (0.37, 0.83)
Periglandular inflamation		
Light 1.1 vs. Light 1.2	352	0.50 (0.40, 0.60)
Virtual 1.1 vs. Virtual 1.2	350	0.62 (0.54, 0.71)
Stromal inflammation		
Light 1.1 vs. Light 1.2	352	0.32 (0.21, 0.43)
Virtual 1.1 vs. Virtual 1.2	350	0.59 (0.50, 0.67)
0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cohen's kappa		

Supplementary Figure S5. Bland and Altman plot of the intra-method intra-observer agreement for the percentage of Gleason pattern 4, evaluated on the core level



Supplementary Figure S6. Bland and Altman plot of the intra-method inter-observer agreement for biopsy core length measured in millimeters, evaluated on the core level



Supplementary Figure S7. Bland and Altman plot of the intra-method inter-observer agreement for the length of tumor in the biopsy core measured in millimeters, evaluated on the core level



Supplementary Figure S8. Intra-method inter-observer agreement for characteristics evaluated on the core level

Comparison		Sample size	Cohen's kappa (95% CI)
Primary Gleason pattern			
Light 1.1 vs. Light 2	⊨⊷⊣	257	0.89 (0.84, 0.94)
Light 1.2 vs. Light 2	⊢_ ♦I	255	0.72 (0.65, 0.79)
Virtual 1.1 vs. Virtual 2	⊢ •−1	243	0.80 (0.73, 0.87)
Virtual 1.2 vs. Virtual 2	⊢_ ♦I	242	0.78 (0.70, 0.85)
Secondary Gleason pattern			
Light 1.1 vs. Light 2	⊢ →−1	257	0.74 (0.68, 0.81)
Light 1.2 vs. Light 2	⊢_ ♦I	255	0.58 (0.50, 0.66)
Virtual 1 1 vs. Virtual 2	⊢_ ♦I	243	0.68 (0.61, 0.75)
Virtual 1.2 vs. Virtual 2	⊢	242	0.67 (0.60, 0.74)
Gleason score			0.01 (0.00, 0.1 1)
Light 1 1 vs Light 2	⊢∔ -1	257	0.86 (0.83, 0.90)
Light 1.2 vs. Light 2		255	0.00(0.00, 0.00) 0.76(0.71, 0.81)
Virtual 1 1 vs. Virtual 2	· · · ·	200	0.70(0.71, 0.01) 0.81(0.77, 0.86)
Virtual 1.1 vs. Virtual 2		240	0.01(0.77, 0.00)
Gleason Grade Groups		242	0.01 (0.70, 0.00)
Light 1 1 vs. Light 2		257	
Light 1.1 VS. Light 2		207	0.09(0.00, 0.92)
Light 1.2 VS. Light 2		200	0.00(0.70, 0.04)
Virtual 1.1 VS. Virtual 2		243	0.03(0.00, 0.07)
Virtual 1.2 vs. virtual 2		242	0.83 (0.78, 0.87)
Cribritorm pattern		057	0.50 (0.40, 0.00)
Light 1.1 vs. Light 2		257	0.58 (0.48, 0.68)
Light 1.2 vs. Light 2		255	0.48 (0.38, 0.59)
Virtual 1.1 vs. Virtual 2	⊢	243	0.61 (0.51, 0.71)
Virtual 1.2 vs. Virtual 2	⊢	242	0.61 (0.51, 0.72)
Poorly formed glands			
Light 1.1 vs. Light 2	├ ── ♦ ──- 	257	0.61 (0.52, 0.71)
Light 1.2 vs. Light 2	⊢	255	0.56 (0.45, 0.66)
Virtual 1.1 vs. Virtual 2	├── ✦──┤	243	0.61 (0.50, 0.71)
Virtual 1.2 vs. Virtual 2	⊢	242	0.54 (0.43, 0.65)
Comedonecrosis			
Light 1.1 vs. Light 2	⊢	257	0.64 (0.46, 0.83)
Light 1.2 vs. Light 2	⊢−−−− −	255	0.50 (0.29, 0.71)
Virtual 1.1 vs. Virtual 2	⊢	243	0.51 (0.27, 0.75)
Virtual 1.2 vs. Virtual 2	⊢	242	0.57 (0.34, 0.80)
Perineural invasion			
Light 1.1 vs. Light 2	⊨⊷	257	0.90 (0.84, 0.96)
Light 1.2 vs. Light 2	⊢	255	0.61 (0.49, 0.73)
Virtual 1.1 vs. Virtual 2	⊢⊢i	243	0.38 (0.22, 0.53)
Virtual 1.2 vs. Virtual 2	⊢	242	0.45 (0.30, 0.60)
Intraductal carcinoma			
Light 1.1 vs. Light 2	├──── ↓	257	0.24 (-0.03, 0.51)
Light 1.2 vs. Light 2	└─── ✦───┤	255	0.19 (-0.06, 0.43)
Virtual 1.1 vs. Virtual 2	↓	243	0.14 (-0.15, 0.43)
Virtual 1.2 vs. Virtual 2	↓	242	0.43 (0.02, 0.84)
Mucinous carcinoma			· · · · ·
Light 1.1 vs. Light 2	⊢	257	0.59 (0.33, 0.84)
Light 1.2 vs. Light 2	⊢	255	0.34 (0.05. 0.63)
Virtual 1.1 vs. Virtual 2	├────	243	0.27 (-0.17. 0.72)
Virtual 1.2 vs. Virtual 2	↓ I	242	0.23 (-0.17, 0.64)
			(, , , , , , , , , , , , , , , , ,
	-0.2 0.0 0.2 0.4 0.6 0.8 1.0		
	Cohen's kappa		

Supplementary Figure S9. Intra-method inter-observer agreement for characteristics evaluated on the slide level

Acute inflammation Light 1.1 vs. Light 2 Light 1.2 vs. Light 2 Virtual 1.1 vs. Virtual 2 Virtual 1.1 vs. Virtual 2 Virtual 1.2 vs. Virtual 2 Chronic inflammation Light 1.1 vs. Light 2 Virtual 1.2 vs. Light 2 Virtual 1.2 vs. Virtual 2 Light 1.1 vs. Light 2 Light 1.2 vs. Virtual 2 Virtual 1.1 vs. Virtual 2 Virtual 1.1 vs. Virtual 2 Virtual 1.1 vs. Virtual 2 Virtual 1.2 vs. Virtual 2 </th <th>Comparison</th> <th></th> <th>Sample size</th> <th>Cohen's kappa (95% CI)</th>	Comparison		Sample size	Cohen's kappa (95% CI)
Light 1.1 vs. Light 2 352 0.71 (0.56, 0.85) Light 1.2 vs. Light 2 349 0.45 (0.26, 0.66) Virtual 1.1 vs. Virtual 2 349 0.40 (0.20, 0.56) Chronic inflammation 352 0.68 (0.60, 0.76) Light 1.2 vs. Light 2 349 0.36 (0.29, 0.44) Virtual 1.2 vs. Light 2 349 0.36 (0.29, 0.44) Virtual 1.1 vs. Light 2 349 0.36 (0.29, 0.44) Virtual 1.2 vs. Virtual 2 349 0.36 (0.29, 0.44) Virtual 1.2 vs. Virtual 2 349 0.36 (0.29, 0.44) Virtual 1.2 vs. Virtual 2 347 0.31 (0.22, 0.38) High-grade prostatic intraepithelial neoplasia 352 0.68 (0.51, 0.86) Light 1.1 vs. Light 2 349 0.32 (0.06, 0.34) Virtual 1.2 vs. Virtual 2 349 0.23 (0.06, 0.33) Virtual 1.2 vs. Virtual 2 349 0.34 (0.18, 0.44) Virtual 1.1 vs. Light 2 349 352 0.60 (0.39, 0.83) Virtual 1.2 vs. Virtual 2 349 0.34 (0.18, 0.44) 0.34 (0.18, 0.44) Virtual 1.2 vs. Virtual 2 349 0.34 (0.18, 0.44) 0.34 (0.18, 0.44) Virtual 1.2 vs. Virtual 2	Acute inflammation			
Light 1.2 vs. Light 2	Light 1.1 vs. Light 2	├──── ✦────┤	352	0.71 (0.56, 0.87)
Virtual 1.1 vs. Virtual 2 Image: Constraint of the second sec	Light 1.2 vs. Light 2	⊢ I	352	0.42 (0.23, 0.61)
Virtual 1.2 vs. Virtual 2 Image: Constraint of the second sec	Virtual 1.1 vs. Virtual 2	├──── ↓	349	0.45 (0.26, 0.64)
Chronic inflammation Light 1.1 vs. Light 2	Virtual 1.2 vs. Virtual 2	⊢ I	347	0.40 (0.20, 0.59)
Light 1.1 vs. Light 2 Image: Constraint of the second	Chronic inflammation			
Light 1.2 vs. Light 2 Image: Constraint of the second	Light 1.1 vs. Light 2	├✦┤	352	0.68 (0.60, 0.76)
Virtual 1.1 vs. Virtual 2 Image: Constraint of the second sec	Light 1.2 vs. Light 2	├──◆	352	0.49 (0.40, 0.59)
Virtual 1.2 vs. Virtual 2 Image: Constraint of the second sec	Virtual 1.1 vs. Virtual 2	⊢_ ♦I	349	0.36 (0.29, 0.44)
High-grade prostatic intraepithelial neoplasia Light 1.1 vs. Light 2 352 0.68 (0.51, 0.89) Light 1.2 vs. Light 2 352 0.27 (0.06, 0.49) Virtual 1.1 vs. Virtual 2 349 0.23 (0.06, 0.39) Virtual 1.2 vs. Virtual 2 347 0.15 (-0.02, 0.39) Intraglandular inflamation 352 0.61 (0.45, 0.76) Light 1.2 vs. Light 2 447 352 0.38 (0.20, 0.56) Virtual 1.1 vs. Light 2 447 349 0.34 (0.18, 0.45) Virtual 1.1 vs. Virtual 2 447 349 0.34 (0.18, 0.45) Virtual 1.2 vs. Light 2 447 347 0.38 (0.21, 0.56) Postatrophic hyperplasia 352 0.60 (0.39, 0.82) 347 0.38 (0.21, 0.56) Light 1.1 vs. Light 2 447 352 0.60 (0.39, 0.82) 0.54 (0.22, 0.7) Virtual 1.1 vs. Light 2 447 352 0.60 (0.29, 0.7) 0.56 (0.22, 0.7) Virtual 1.1 vs. Light 2 447 352 0.46 (0.22, 0.7) 0.54 (0.31, 0.76)	Virtual 1.2 vs. Virtual 2	⊢	347	0.31 (0.22, 0.39)
Light 1.1 vs. Light 2	High-grade prostatic intraepithelial r	eoplasia		
Light 1.2 vs. Light 2 Image: Constraint of the second	Light 1.1 vs. Light 2	⊢−−−− −	352	0.68 (0.51, 0.85)
Virtual 1.1 vs. Virtual 2 Image: state of the stat	Light 1.2 vs. Light 2	├──── ↓	352	0.27 (0.06, 0.48)
Virtual 1.2 vs. Virtual 2 Intraglandular inflamation 347 0.15 (-0.02, 0.3) Intraglandular inflamation 1 352 0.61 (0.45, 0.7) Light 1.1 vs. Light 2 Image: Comparison of the system of the syst	Virtual 1.1 vs. Virtual 2	├────	349	0.23 (0.06, 0.39)
Intraglandular inflamation Light 1.1 vs. Light 2 352 0.61 (0.45, 0.76) Light 1.2 vs. Light 2 352 0.38 (0.20, 0.56) Virtual 1.1 vs. Virtual 2 349 0.34 (0.18, 0.45) Virtual 1.2 vs. Virtual 2 347 0.38 (0.21, 0.56) Postatrophic hyperplasia 352 0.60 (0.39, 0.82) Light 1.2 vs. Light 2 4 352 0.60 (0.29, 0.76) Virtual 1.1 vs. Light 2 4 352 0.60 (0.29, 0.76) Virtual 1.1 vs. Virtual 2 4 352 0.46 (0.22, 0.77)	Virtual 1.2 vs. Virtual 2	↓ • • • • • • • • • • • •	347	0.15 (-0.02, 0.32)
Light 1.1 vs. Light 2 Image: Constraint of the second	Intraglandular inflamation			
Light 1.2 vs. Light 2 Image: Constraint of the second	Light 1.1 vs. Light 2	⊢−−−− −	352	0.61 (0.45, 0.78)
Virtual 1.1 vs. Virtual 2 Image: Constraint of the second sec	Light 1.2 vs. Light 2	⊢−−−− −	352	0.38 (0.20, 0.56)
Virtual 1.2 vs. Virtual 2	Virtual 1.1 vs. Virtual 2	⊢−−− +	349	0.34 (0.18, 0.49)
Postatrophic hyperplasia	Virtual 1.2 vs. Virtual 2	⊢ I	347	0.38 (0.21, 0.56)
Light 1.1 vs. Light 2	Postatrophic hyperplasia			
Light 1.2 vs. Light 2 - 352 0.46 (0.22, 0.7 Virtual 1.1 vs. Virtual 2 - 349 0.54 (0.31, 0.7	Light 1.1 vs. Light 2	⊢ I	352	0.60 (0.39, 0.82)
Virtual 1.1 vs. Virtual 2	Light 1.2 vs. Light 2	├────	352	0.46 (0.22, 0.71)
	Virtual 1.1 vs. Virtual 2	├──── ↓	349	0.54 (0.31, 0.78)
Virtual 1.2 vs. Virtual 2 - 347 0.66 (0.42, 0.89	Virtual 1.2 vs. Virtual 2	├────	347	0.66 (0.42, 0.89)
Periglandular inflamation	Periglandular inflamation			
Light 1.1 vs. Light 2	Light 1.1 vs. Light 2	⊢	352	0.40 (0.29, 0.51)
Light 1.2 vs. Light 2 - 352 0.29 (0.17, 0.4	Light 1.2 vs. Light 2	└───↓	352	0.29 (0.17, 0.41)
Virtual 1.1 vs. Virtual 2 - 349 0.39 (0.30, 0.4)	Virtual 1.1 vs. Virtual 2	⊢ →→	349	0.39 (0.30, 0.48)
Virtual 1.2 vs. Virtual 2 - 347 0.34 (0.25, 0.44	Virtual 1.2 vs. Virtual 2	⊢∔ ↓	347	0.34 (0.25, 0.44)
Stromal inflammation	Stromal inflammation			. ,
Light 1.1 vs. Light 2 - 352 0.49 (0.38, 0.59	Light 1.1 vs. Light 2	⊢	352	0.49 (0.38, 0.59)
Light 1.2 vs. Light 2	Light 1.2 vs. Light 2	⊢ →→	352	0.43 (0.32, 0.53)
Virtual 1.1 vs. Virtual 2 - 349 0.28 (0.19, 0.3)	Virtual 1.1 vs. Virtual 2	⊢ ♦I	349	0.28 (0.19, 0.37)
Virtual 1.2 vs. Virtual 2	Virtual 1.2 vs. Virtual 2	⊢	347	0.30 (0.20, 0.39)
-0.1 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0		-0.1 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0		
Cohen's kappa		Cohen's kappa		

Supplementary Figure S10. Bland and Altman plot of the intra-method inter-observer agreement for the percentage of Gleason pattern 4, evaluated on the core level



Supplementary Figure S11. Bland and Altman plot of the inter-method intra-observer agreement for the biopsy core length measured in millimeters, evaluated on the core level



Supplementary Figure S12. Bland and Altman plot of the inter-method intra-observer agreement for the length of tumor in the biopsy core measured in millimeters, evaluated on the core level



Supplementary Figure S13. Inter-method intra-observer agreement for characteristics evaluated on the core level

Comparison				Sample size	Cohen's kappa (95% CI)
Primary Gleason pattern					
Light 1.1 vs. Virtual 1.1			⊢ •1	252	0.88 (0.83, 0.94)
Light 1.1 vs. Virtual 1.2			⊢♦ −1	251	0.86(0.80, 0.92)
Light 2 vs. Virtual 2			⊢	243	0.69(0.62, 0.77)
Light 1.2 vs. Virtual 1.1			⊢	251	0.80(0.73, 0.87)
Light 1.2 vs. Virtual 1.2			⊢ •−-1	250	0.81 (0.74, 0.88)
Secondary Gleason pattern				200	
Light 1.1 vs. Virtual 1.1			⊢ →1	252	0.68 (0.61, 0.76)
Light 1.1 vs. Virtual 1.2			⊢	251	0.75 (0.69, 0.82)
Light 2 vs. Virtual 2		⊢	- -	243	0.59(0.51, 0.67)
Light 1.2 vs. Virtual 1.1			⊢ ♦1	251	0.68 (0.61, 0.76)
Light 1.2 vs. Virtual 1.2			⊢_♦ 1	250	0.69 (0.62, 0.76)
Gleason score				200	0100 (0102, 0110)
Light 1 1 vs. Virtual 1 1			⊢+-1	252	0 84 (0 80 0 89)
Light 1 1 vs. Virtual 1 2			⊢♦ −1	251	0.85 (0.80, 0.89)
Light 2 vs. Virtual 2			⊢♦ −1	243	0.77(0.72, 0.82)
Light 1.2 vs. Virtual 1.1			⊢♦ −1	251	0.82(0.77, 0.87)
Light 1.2 vs. Virtual 1.2			⊢♦ −1	250	0.81 (0.76, 0.86)
Gleason Grade Groups					
Light 1.1 vs. Virtual 1.1			⊢⊷⊣	252	0.87 (0.84, 0.91)
Light 1.1 vs. Virtual 1.2			⊢♦ −1	251	0.86 (0.82, 0.90)
Light 2 vs. Virtual 2			⊢ •−1	243	0.81(0.76, 0.85)
Light 1.2 vs. Virtual 1.1			H •-1	251	0.83 (0.79, 0.88)
Light 1.2 vs. Virtual 1.2			⊢⊷ ⊣	250	0.83 (0.79, 0.88)
Cribriform pattern					0.000 (0.00, 0.000)
Light 1.1 vs. Virtual 1.1		F		252	0.64 (0.54, 0.74)
Light 1.1 vs. Virtual 1.2		—	◆ 1	251	0.57 (0.47, 0.68)
Light 2 vs. Virtual 2		⊢ →		243	0.49 (0.39, 0.60)
Light 1.2 vs. Virtual 1.1			⊢	251	0.68(0.59, 0.78)
Light 1.2 vs. Virtual 1.2		⊢	+ 1	250	0.61(0.51, 0.71)
Poorly formed glands					
Light 1.1 vs. Virtual 1.1		⊢ ⊸•	⊢	252	0.55 (0.44, 0.66)
Light 1.1 vs. Virtual 1.2		⊢	→	251	0.62 (0.51, 0.72)
Light 2 vs. Virtual 2		⊢ →		243	0.53 (0.42, 0.64)
Light 1.2 vs. Virtual 1.1			⊢	251	0.68 (0.58, 0.78)
Light 1.2 vs. Virtual 1.2		⊢		250	0.61 (0.51, 0.72)
Comedonecrosis					(, , ,
Light 1.1 vs. Virtual 1.1			⊢−−−−−	252	0.79 (0.61, 0.97)
Light 1.1 vs. Virtual 1.2			⊢−−−−	251	0.84 (0.68, 0.99)
Light 2 vs. Virtual 2		⊢	i	243	0.45 (0.24, 0.65)
Light 1.2 vs. Virtual 1.1		—		251	0.68 (0.46, 0.90)
Light 1.2 vs. Virtual 1.2		F	+	250	0.74 (0.54, 0.94)
Perineural invasion					,
Light 1.1 vs. Virtual 1.1		F	+	252	0.65 (0.53, 0.77)
Light 1.1 vs. Virtual 1.2		F	+ I	251	0.65 (0.53, 0.77)
Light 2 vs. Virtual 2		⊢ →		243	0.49 (0.36, 0.63)
Light 1.2 vs. Virtual 1.1		H	- • I	251	0.60 (0.47, 0.74)
Light 1.2 vs. Virtual 1.2		⊢ →	—	250	0.52 (0.38, 0.66)
Intraductal carcinoma					
Light 1.1 vs. Virtual 1.1	⊢	•		252	0.44 (0.03, 0.84)
Light 1.1 vs. Virtual 1.2	H	+		251	0.33 (-0.16, 0.82)
Light 2 vs. Virtual 2	⊢	I		243	0.07 (-0.12, 0.27)
Light 1.2 vs. Virtual 1.1		•	I	251	0.32 (-0.03, 0.67)
Light 1.2 vs. Virtual 1.2		H	◆ 1	250	0.66 (0.30, 1.00)
Mucinous carcinoma					
Light 1.1 vs. Virtual 1.1		H	→	252	0.69 (0.37, 1.00)
Light 1.1 vs. Virtual 1.2		F	+ I	251	0.72 (0.42, 1.00)
Light 2 vs. Virtual 2	⊢◆			243	0.10 (-0.12, 0.32)
Light 1.2 vs. Virtual 1.1	F		، ا	251	0.56 (0.12, 1.00)
Light 1.2 vs. Virtual 1.2		H	→	250	0.75 (0.40, 1.00)
	Г <u>Т</u>	1 1			
	-0.2 0.0	0.2 0.4	0.6 0.8 1.0		
		Cohen's kapp	a		

Supplementary Figure S14. Inter-method intra-observer agreement for characteristics evaluated on the slide level

Comparison		Sample size	Cohen's kappa (95% CI)
Acute inflammation			
Light 1.1 vs. Virtual 1.1	⊢ i	353	0.51 (0.34, 0.68)
Light 1.1 vs. Virtual 1.2	⊢ I	351	0.63 (0.47, 0.78)
Light 2 vs. Virtual 2	⊢ i	350	0.49 (0.27, 0.72)
Light 1.2 vs. Virtual 1.1	⊢ I	354	0.47 (0.30, 0.64)
Light 1.2 vs. Virtual 1.2	⊢ I	352	0.63 (0.47, 0.78)
Chronic inflammation			
Light 1.1 vs. Virtual 1.1	⊢ →→→	353	0.38 (0.30, 0.46)
Light 1.1 vs. Virtual 1.2	⊢ ♦1	351	0.40 (0.32, 0.48)
Light 2 vs. Virtual 2	⊢ →	350	0.39 (0.29, 0.49)
Light 1.2 vs. Virtual 1.1	⊢_ •I	354	0.41 (0.33, 0.49)
Light 1.2 vs. Virtual 1.2	⊢	352	0.38 (0.29, 0.46)
High-grade prostatic intraepithelial neopla	isia		
Light 1.1 vs. Virtual 1.1	⊢−−−− − Ι	353	0.29 (0.12, 0.45)
Light 1.1 vs. Virtual 1.2	├────	351	0.46 (0.28, 0.65)
Light 2 vs. Virtual 2	├───	350	0.14 (-0.04, 0.32)
Light 1.2 vs. Virtual 1.1	↓ ↓ ↓	354	0.35 (0.18, 0.53)
Light 1.2 vs. Virtual 1.2	⊢−−−−− +	352	0.46 (0.26, 0.65)
Intraglandular inflamation			
Light 1.1 vs. Virtual 1.1	⊢ →	353	0.55 (0.41, 0.69)
Light 1.1 vs. Virtual 1.2	⊢	351	0.57 (0.42, 0.72)
Light 2 vs. Virtual 2	⊢−−−−− −−−−−−−−−−−−−−−−−−−1	350	0.65 (0.46, 0.84)
Light 1.2 vs. Virtual 1.1	⊢	354	0.57 (0.43, 0.71)
Light 1.2 vs. Virtual 1.2	⊢−−− +	352	0.62 (0.48, 0.76)
Postatrophic hyperplasia			
Light 1.1 vs. Virtual 1.1	└──── ↓	353	0.33 (0.10, 0.56)
Light 1.1 vs. Virtual 1.2	↓	351	0.48 (0.23, 0.73)
Light 2 vs. Virtual 2	├───	350	0.20 (-0.02, 0.42)
Light 1.2 vs. Virtual 1.1	├──── ↓	354	0.40 (0.14, 0.65)
Light 1.2 vs. Virtual 1.2	├────	352	0.59 (0.33, 0.85)
Periglandular inflamation			
Light 1.1 vs. Virtual 1.1	├── ◆──┤	353	0.46 (0.37, 0.55)
Light 1.1 vs. Virtual 1.2	⊢ →	351	0.34 (0.24, 0.44)
Light 2 vs. Virtual 2	⊢ → − − 1	350	0.32 (0.20, 0.44)
Light 1.2 vs. Virtual 1.1	⊢	354	0.44 (0.35, 0.53)
Light 1.2 vs. Virtual 1.2	⊢ I	352	0.44 (0.34, 0.53)
Stromal inflammation			
Light 1.1 vs. Virtual 1.1	⊢ → 1	353	0.29 (0.21, 0.38)
Light 1.1 vs. Virtual 1.2	⊢ →	351	0.34 (0.24, 0.43)
Light 2 vs. Virtual 2	⊢I	350	0.36 (0.25, 0.47)
Light 1.2 vs. Virtual 1.1	├──◆	354	0.41 (0.32, 0.50)
Light 1.2 vs. Virtual 1.2	⊢	352	0.36 (0.26, 0.46)
F			
-0.1	0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0		
	Cohen's kappa		

Supplementary Figure S15. Bland and Altman plot of the inter-method intra-observer agreement for the percentage of Gleason pattern 4, evaluated on the core level



Supplementary Figure S16. Bland and Altman plot of the inter-method inter-observer agreement for the biopsy core length measured in millimeters, evaluated on the core level

Abbreviations: Light 1.1, First review by Reviewer 1 on light microscopy; Virtual 2, Reviewer 2 on virtual microscopy; Light 2, Reviewer 2 on light microscopy; Virtual 1.1, First review by Reviewer 1 on virtual microscopy; Virtual 1.2, Second review by Reviewer 1 on virtual microscopy; Light 1.2, Second review by Reviewer 1 on light microscopy



Supplementary Figure S17. Bland and Altman plot of the inter-method inter-observer agreement for the length of tumor in the biopsy core measured in millimeters, evaluated on the core level

Abbreviations: Light 1.1, First review by Reviewer 1 on light microscopy; Virtual 2, Reviewer 2 on virtual microscopy; Light 2, Reviewer 2 on light microscopy; Virtual 1.1, First review by Reviewer 1 on virtual microscopy; Virtual 1.2, Second review by Reviewer 1 on virtual microscopy; Light 1.2, Second review by Reviewer 1 on light microscopy



Supplementary Figure S18. Inter-method inter-observer agreement for characteristics evaluated on the core level

Abbreviations: Light 1.1, First review by Reviewer 1 on light microscopy; Virtual 2, Reviewer 2 on virtual microscopy; Light 2, Reviewer 2 on light microscopy; Virtual 1.1, First review by Reviewer 1 on virtual microscopy; Virtual 1.2, second review by Reviewer 1 on virtual microscopy; Light 1.2, second review by Reviewer 1 on light microscopy

Comparison	Sample size	Cohen's kappa (95% CI)
Primary Gleason pattern		
Light 1.1 vs. Virtual 2	→ 243	0.76 (0.68, 0.83)
Light 2 vs. Virtual 1.1	→→ 251	0.79 (0.73, 0.86)
Light 2 vs. Virtual 1.2	⊷ 250	0.80 (0.73, 0.86)
Light 1.2 vs. Virtual 2	→→ 243	0.88 (0.82, 0.94)
Secondary Gleason pattern		
Light 1.1 vs. Virtual 2	+ 243	0.62 (0.54, 0.70)
Light 2 vs. Virtual 1.1	251	0.53 (0.45, 0.62)
Light 2 vs. Virtual 1.2	⊣ 250	0.65 (0.57, 0.72)
Light 1.2 vs. Virtual 2	⊷→ 243	0.77 (0.71, 0.84)
Gleason score		(, , ,
Light 1.1 vs. Virtual 2	⊷ 243	0.80 (0.75, 0.85)
Light 2 vs. Virtual 1.1	⊷ 251	0.76 (0.71, 0.81)
Light 2 vs. Virtual 1.2	⊷ 250	0.79 (0.74, 0.84)
Light 1.2 vs. Virtual 2	⊷→ 243	0.87 (0.83, 0.91)
Gleason Grade Groups		(, , ,
Light 1.1 vs. Virtual 2	⊷→ 243	0.82 (0.78, 0.86)
Light 2 vs. Virtual 1.1	⊷→ 251	0.81 (0.77, 0.85)
Light 2 vs. Virtual 1.2	⊷ 250	0.82 (0.78, 0.87)
Light 1.2 vs. Virtual 2	⊷ 243	0.88 (0.84, 0.91)
Cribriform pattern		
Light 1.1 vs. Virtual 2	243	0.51 (0.40, 0.62)
Light 2 vs. Virtual 1.1	251	0.48 (0.37, 0.59)
Light 2 vs. Virtual 1.2	250	0.46 (0.35, 0.57)
Light 1.2 vs. Virtual 2	243	0.54 (0.44, 0.65)
Poorly formed glands		
Light 1.1 vs. Virtual 2	243	0.57 (0.46, 0.68)
Light 2 vs. Virtual 1.1	251	0.49 (0.38, 0.60)
Light 2 vs. Virtual 1.2	250	0.53 (0.42, 0.64)
Light 1.2 vs. Virtual 2	— 243	0.66 (0.57, 0.76)
Comedonecrosis		
Light 1.1 vs. Virtual 2	243	0.62 (0.39, 0.85)
Light 2 vs. Virtual 1.1	251	0.68 (0.50, 0.86)
Light 2 vs. Virtual 1.2	250	0.66 (0.48, 0.84)
Light 1.2 vs. Virtual 2	243	0.59 (0.34, 0.83)
Perineural invasion		(, ,
Light 1.1 vs. Virtual 2	243	0.47 (0.33, 0.60)
Light 2 vs. Virtual 1.1	— 251	0.64 (0.52, 0.76)
Light 2 vs. Virtual 1.2	 250	0.66 (0.55, 0.78)
Light 1.2 vs. Virtual 2	243	0.53 (0.38, 0.68)
Intraductal carcinoma		
Light 1.1 vs. Virtual 2	⊣ 243	0.28 (-0.16, 0.72)
Light 2 vs. Virtual 1.1	251	0.36 (0.09, 0.62)
Light 2 vs. Virtual 1.2	250	0.31 (0.03, 0.59)
Light 1.2 vs. Virtual 2	243	0.59 (0.22, 0.96)
Mucinous carcinoma		(, , ,
Light 1.1 vs. Virtual 2	243	0.24 (-0.17, 0.64)
Light 2 vs. Virtual 1.1	— 251	0.49 (0.21, 0.76)
Light 2 vs. Virtual 1.2	250	0.51 (0.24, 0.79)
Light 1.2 vs. Virtual 2	— 243	0.32 (-0.17, 0.82)
~ 		····,-···/
-0.2 0.0 0.2 0.4 0.6	0.8 1.0	
Cohen's kappa		

Supplementary Figure S19. Inter-method inter-observer agreement for characteristics evaluated on the slide level

Abbreviations: CI, confidence interval; Light 1.1, First review by Reviewer 1 on light microscopy; Virtual 2, Reviewer 2 on virtual microscopy; Light 2, Reviewer 2 on light microscopy; Virtual 1.1, First review by Reviewer 1 on virtual microscopy; Virtual 1.2, second review by Reviewer 1 on virtual microscopy; Light 1.2, second review by Reviewer 1 on virtual microscopy; Light 1.2, second review by Reviewer 1 on virtual microscopy; Light 1.2, second review by Reviewer 1 on virtual microscopy; Light 1.2, second review by Reviewer 1 on virtual microscopy; Light 1.2, second review by Reviewer 1 on virtual microscopy; Light 1.2, second review by Reviewer 1 on virtual microscopy; Light 1.2, second review by Reviewer 1 on virtual microscopy; Light 1.2, second review by Reviewer 1 on light microscopy; Light 1.2, second review by Reviewer 1 on light microscopy; Light 1.2, second review by Reviewer 1 on virtual microscopy; Light 1.2, second review by Reviewer 1 on light microscopy; Light 1.2, second review by Reviewer 1 on light microscopy; Light 1.2, second review by Reviewer 1 on light microscopy; Light 1.2, second review by Reviewer 1 on light microscopy; Light 1.2, second review by Reviewer 1 on light microscopy; Light 1.2, second review by Reviewer 1 on light microscopy; Light 1.2, second review by Reviewer 1 on light microscopy; Light 1.2, second review by Reviewer 1 on light microscopy; Light 1.2, second review by Reviewer 1 on light microscopy; Light 1.2, second review by Reviewer 1 on light microscopy; Light 1.2, second review by Reviewer 1 on light microscopy; Light 1.2, second review by Reviewer 1 on light microscopy; Light 1.2, second review by Reviewer 1 on light microscopy; Light 1.2, second review by Reviewer 1 on light microscopy; Light 1.2, second reviewer 1

Comparison		Sample size	Cohen's kappa (95% Cl)
Acute inflammation			
Light 1.1 vs. Virtual 2	↓ I	350	0.46 (0.27, 0.65)
Light 2 vs. Virtual 1.1	⊢ i	353	0.50 (0.32, 0.69)
Light 2 vs. Virtual 1.2	⊢	351	0.60 (0.43, 0.77)
Light 1.2 vs. Virtual 2		350	0.30 (0.11, 0.50)
Chronic inflammation			
Light 1.1 vs. Virtual 2	⊢	350	0.44 (0.34, 0.54)
Light 2 vs. Virtual 1.1	⊢	353	0.31 (0.24, 0.38)
Light 2 vs. Virtual 1.2	⊢	351	0.33 (0.25, 0.40)
Light 1.2 vs. Virtual 2	⊢	350	0.44 (0.35, 0.54)
High-grade prostatic intraepithelial neoplasia			
Light 1.1 vs. Virtual 2		350	0.16 (-0.02, 0.34)
Light 2 vs. Virtual 1.1	♦1	353	0.26 (0.09, 0.43)
Light 2 vs. Virtual 1.2	⊢−−−−− 1	351	0.39 (0.20, 0.59)
Light 1.2 vs. Virtual 2	→	350	0.27 (0.06, 0.48)
Intraglandular inflamation			
Light 1.1 vs. Virtual 2	└─── ◆────1	350	0.49 (0.31, 0.67)
Light 2 vs. Virtual 1.1	⊢−−−− 1	353	0.46 (0.31, 0.61)
Light 2 vs. Virtual 1.2	⊢ I	351	0.54 (0.37, 0.70)
Light 1.2 vs. Virtual 2		350	0.25 (0.08, 0.43)
Postatrophic hyperplasia			
Light 1.1 vs. Virtual 2	⊢ I	350	0.51 (0.25, 0.76)
Light 2 vs. Virtual 1.1	├──── ↓	353	0.49 (0.27, 0.72)
Light 2 vs. Virtual 1.2	→	351	0.35 (0.11, 0.58)
Light 1.2 vs. Virtual 2	→	350	0.40 (0.12, 0.69)
Periglandular inflamation			
Light 1.1 vs. Virtual 2	⊢ I	350	0.37 (0.26, 0.48)
Light 2 vs. Virtual 1.1	♦ !	353	0.18 (0.10, 0.26)
Light 2 vs. Virtual 1.2	♦ —1	351	0.18 (0.10, 0.27)
Light 1.2 vs. Virtual 2	⊢	350	0.37 (0.26, 0.49)
Stromal inflammation			
Light 1.1 vs. Virtual 2	└── ◆───1	350	0.37 (0.25, 0.48)
Light 2 vs. Virtual 1.1	⊢	353	0.30 (0.21, 0.39)
Light 2 vs. Virtual 1.2	└── ♣───¹	351	0.32 (0.22, 0.41)
Light 1.2 vs. Virtual 2	↓ • • • • • • • • • • • • • • • • • • •	350	0.38 (0.27, 0.48)
-0.1 0.0 0.1 (0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Coben's kanna		
	contro happa		

Supplementary Figure S20. Bland and Altman plot of the inter-method inter-observer agreement for the percentage of Gleason pattern 4, evaluated on the core level

Abbreviations: Light1.1, First review by Reviewer 1 on light microscopy; Virtual2, Reviewer 2 on virtual microscopy; Light2, Reviewer2 on light microscopy; Virtual1.1, First review by Reviewer1 on virtual microscopy; Virtual1.2, second review by Reviewer1 on virtual microscopy; Light1.2, second review by Reviewer1 on light microscopy



Supplementary Figure S21. Bland and Altman plot of the intra-method intra-observer agreement for the total biopsy length measured in millimeters, evaluated on the case level



Supplementary Figure S22. Bland and Altman plot of the intra-method intra-observer agreement for the total length of tumor in the biopsy measured in millimeters, evaluated on the case level



Supplementary Figure S23. Intra-method intra-observer agreement evaluated on the case level

Comparison		Sample size	Cohen's kappa (95% CI)
Primary Gleason pattern			
Light 1.1 vs. Light 1.2	├ ──── ├	57	0.68 (0.50, 0.85)
Virtual 1.1 vs. Virtual 1.2	⊢ I	58	0.85 (0.72, 0.98)
Secondary Gleason pattern			
Light 1.1 vs. Light 1.2	⊢ I	57	0.69 (0.54, 0.84)
Virtual 1.1 vs. Virtual 1.2	⊢	58	0.82 (0.70, 0.94)
Gleason score			
Light 1.1 vs. Light 1.2	├─── ◆───┤	57	0.88 (0.81, 0.96)
Virtual 1.1 vs. Virtual 1.2	⊢ I	58	0.90 (0.83, 0.97)
Gleason Grade Groups			
Light 1.1 vs. Light 1.2	⊢ +	57	0.89 (0.82, 0.95)
Virtual 1.1 vs. Virtual 1.2	├──◆ ──1	58	0.91 (0.84, 0.98)
Perineural invasion			
Light 1.1 vs. Light 1.2	├────	57	0.69 (0.50, 0.89)
Virtual 1.1 vs. Virtual 1.2	├──── ↓	58	0.64 (0.43, 0.86)
	0.4 0.5 0.6 0.7 0.8 0.9 1.0		
Cohen's kappa			

Supplementary Figure S24. Bland and Altman plot of the intra-method inter-observer agreement for the total biopsy length measured in millimeters, evaluated on the case level



Supplementary Figure S25. Bland and Altman plot of the intra-method inter-observer agreement for the total length of tumor in the biopsy measured in millimeters evaluated on the case level



Supplementary Figure S26. Intra-method inter-observer agreement evaluated on the case level

Comparison		Sample size	Cohen's kappa (95% CI)
Primary Gleason pattern			
Light 1.1 vs. Light 2	├───↓	57	0.89 (0.79, 0.99)
Light 1.2 vs. Light 2	├ ─── ↓	57	0.64 (0.47, 0.80)
Virtual 1.1 vs. Virtual 2	├ ─── ↓	58	0.75 (0.59, 0.91)
Virtual 1.2 vs. Virtual 2	⊢ I	58	0.72 (0.56, 0.88)
Secondary Gleason pattern			
Light 1.1 vs. Light 2	⊢ I	57	0.83 (0.72, 0.95)
Light 1.2 vs. Light 2	├──── ↓	57	0.66 (0.50, 0.82)
Virtual 1.1 vs. Virtual 2	⊢ I	58	0.72 (0.57, 0.86)
Virtual 1.2 vs. Virtual 2	├────	58	0.67 (0.52, 0.82)
Gleason score			
Light 1.1 vs. Light 2	⊢	57	0.96 (0.91, 1.00)
Light 1.2 vs. Light 2	⊢	57	0.87 (0.79, 0.95)
Virtual 1.1 vs. Virtual 2	⊢ ♦I	58	0.87 (0.79, 0.95)
Virtual 1.2 vs. Virtual 2	⊢ I	58	0.83 (0.73, 0.93)
Gleason Grade Groups			
Light 1.1 vs. Light 2	⊨⊷	57	0.97 (0.93, 1.00)
Light 1.2 vs. Light 2	⊢	57	0.90 (0.83, 0.97)
Virtual 1.1 vs. Virtual 2	⊢ +I	58	0.86 (0.78, 0.94)
Virtual 1.2 vs. Virtual 2	⊢	58	0.84 (0.74, 0.94)
Perineural invasion			
Light 1.1 vs. Light 2	├───↓	57	0.89 (0.76, 1.00)
Light 1.2 vs. Light 2	⊢ +	57	0.73 (0.54, 0.92)
Virtual 1.1 vs. Virtual 2	↓	58	0.40 (0.15, 0.66)
Virtual 1.2 vs. Virtual 2	├──── ↓	58	0.61 (0.39, 0.83)
	0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0		
	Cohen's kappa		

Supplementary Figure S27. Bland and Altman plot of the inter-method intra-observer agreement for the total biopsy length measured in millimeters, evaluated on the case level



Supplementary Figure S28. Bland and Altman plot of the inter-method intra-observer agreement for the total length of tumor in the biopsy measured in millimeters, evaluated on the case level



Supplementary Figure S29. Inter-method intra-observer agreement evaluated on the case level

Comparison		Sample size	Cohen's kappa (95% CI)
Primary Gleason grade			
Light 1.1 vs. Virtual 1.1	├───	57	0.85 (0.72, 0.98)
Light 1.1 vs. Virtual 1.2	⊢ → I	57	0.77 (0.61, 0.92)
Light 2 vs. Virtual 2	⊢	57	0.63 (0.46, 0.80)
Light 1.2 vs. Virtual 1.1	├ ─── ↓	58	0.69 (0.52, 0.87)
Light 1.2 vs. Virtual 1.2	⊢ → I	58	0.67 (0.50, 0.85)
Secondary Gleason grade			
Light 1.1 vs. Virtual 1.1	├ ─── ↓	57	0.77 (0.63, 0.90)
Light 1.1 vs. Virtual 1.2	⊢	57	0.86 (0.75, 0.97)
Light 2 vs. Virtual 2	↓ ↓ ↓	57	0.55 (0.37, 0.72)
Light 1.2 vs. Virtual 1.1	├ ─── ↓	58	0.70 (0.55, 0.84)
Light 1.2 vs. Virtual 1.2	⊢ I	58	0.69 (0.55, 0.84)
Gleason score			
Light 1.1 vs. Virtual 1.1	⊢ I	57	0.90 (0.81, 0.98)
Light 1.1 vs. Virtual 1.2	⊢	57	0.88 (0.80, 0.97)
Light 2 vs. Virtual 2	⊢	57	0.82 (0.71, 0.92)
Light 1.2 vs. Virtual 1.1	⊢ +	58	0.87 (0.78, 0.96)
Light 1.2 vs. Virtual 1.2	⊢	58	0.83 (0.72, 0.93)
Gleason Grade Groups			
Light 1.1 vs. Virtual 1.1	⊢ ♦	57	0.91 (0.83, 0.99)
Light 1.1 vs. Virtual 1.2	⊢	57	0.86 (0.76, 0.97)
Light 2 vs. Virtual 2	├─── ✦───┤	57	0.85 (0.75, 0.94)
Light 1.2 vs. Virtual 1.1	├ ─── ↓	58	0.85 (0.75, 0.94)
Light 1.2 vs. Virtual 1.2	⊢⊢	58	0.83 (0.72, 0.94)
Perineural invasion			
Light 1.1 vs. Virtual 1.1	⊢	57	0.69 (0.50, 0.89)
Light 1.1 vs. Virtual 1.2	├ ──── ├	57	0.73 (0.55, 0.92)
Light 2 vs. Virtual 2	├────	57	0.54 (0.31, 0.77)
Light 1.2 vs. Virtual 1.1	├ ──── ├	58	0.52 (0.28, 0.76)
Light 1.2 vs. Virtual 1.2	⊢	58	0.72 (0.53, 0.92)
	0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0		
	Cohen's kappa		
	Contro Happa		

Supplementary Figure S30. Bland and Altman plot of the inter-method inter-observer agreement for the total biopsy length measured in millimeters, evaluated on the case level

Abbreviations: Light 1.1, First review by Reviewer 1 on light microscopy; Virtual 2, Reviewer 2 on virtual microscopy; Light 2, Reviewer 2 on light microscopy; Virtual 1.1, First review by Reviewer 1 on virtual microscopy; Virtual 1.2, second review by Reviewer 1 on virtual microscopy; Light 1.2, second review by Reviewer 1 on light microscopy



Supplementary Figure S31. Bland and Altman plot of the inter-method inter-observer agreement for the total length of tumor in the biopsy measured in millimeters, evaluated on the case level

Abbreviations: Light 1.1, First review by Reviewer 1 on light microscopy; Virtual 2, Reviewer 2 on virtual microscopy; Light 2, Reviewer 2 on light microscopy; Virtual 1.1, First review by Reviewer 1 on virtual microscopy; Virtual 1.2, second review by Reviewer 1 on virtual microscopy; Light 1.2, second review by Reviewer 1 on light microscopy

Note: Red lines show limits of agreement when outlier was removed from the analysis



Supplementary Figure S32. Inter-method inter-observer agreement evaluated on the case level

Abbreviations: Light 1.1, First review by Reviewer 1 on light microscopy; Virtual 2, Reviewer 2 on virtual microscopy; Light 2, Reviewer 2 on light microscopy; Virtual 1.1, First review by Reviewer 1 on virtual microscopy; Virtual 1.2, second review by Reviewer 1 on virtual microscopy; Light 1.2, second review by Reviewer 1 on light microscopy

Comparison		Sample size	Cohen's kappa (95% CI)
Primary Gleason grade			
Light 1.1 vs. Virtual 2	↓	57	0.66 (0.49, 0.84)
Light 2 vs. Virtual 1.1	⊢ I	57	0.80 (0.66, 0.94)
Light 2 vs. Virtual 1.2	⊢ I	57	0.72 (0.56, 0.88)
Light 1.2 vs. Virtual 2	⊢ I	58	0.82 (0.68, 0.97)
Secondary Gleason grade			
Light 1.1 vs. Virtual 2	├────	57	0.62 (0.45, 0.78)
Light 2 vs. Virtual 1.1	├ ──── ├	57	0.65 (0.48, 0.81)
Light 2 vs. Virtual 1.2	├ ──── ├	57	0.74 (0.60, 0.88)
Light 1.2 vs. Virtual 2	⊢ I	58	0.85 (0.75, 0.96)
Gleason score			
Light 1.1 vs. Virtual 2	⊢	57	0.83 (0.72, 0.93)
Light 2 vs. Virtual 1.1	⊢	57	0.85 (0.76, 0.94)
Light 2 vs. Virtual 1.2	⊢	57	0.87 (0.78, 0.96)
Light 1.2 vs. Virtual 2	⊢	58	0.94 (0.88, 1.00)
Gleason Grade Groups			
Light 1.1 vs. Virtual 2	⊢ →	57	0.83 (0.74, 0.93)
Light 2 vs. Virtual 1.1	⊢ →	57	0.90 (0.81, 0.98)
Light 2 vs. Virtual 1.2	⊢	57	0.87 (0.78, 0.97)
Light 1.2 vs. Virtual 2	⊢	58	0.93 (0.85, 1.00)
Perineural invasion			
Light 1.1 vs. Virtual 2	├────	57	0.58 (0.36, 0.80)
Light 2 vs. Virtual 1.1	↓	57	0.65 (0.44, 0.86)
Light 2 vs. Virtual 1.2	├ ──── ├	57	0.69 (0.49, 0.89)
Light 1.2 vs. Virtual 2	↓	58	0.64 (0.43, 0.86)
	0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0		
	Cohen's kappa		